Uveal melanoma characterized by the presence of intermediate cells which are similar to but smaller than epithelioid cells.
Comprehensive, easy-to-understand information about this condition
How we create this content →The limited documentation surrounding intermediate cell type uveal melanoma is primarily due to its rarity, which restricts the volume of systematic clinical studies. Additionally, the lack of identified genetic markers and phenotypic characterization further complicates the understanding of this condition. As research continues, there is hope for more comprehensive insights.
To navigate your care effectively, consider seeking a specialist in ocular oncology or a medical oncologist with experience in melanoma. It may also be beneficial to connect with a genetic counselor to discuss any potential genetic implications, even though no specific genes have been identified. For further resources, the National Organization for Rare Disorders (NORD) offers support and information at rarediseases.org. Additionally, inquire about any natural history studies that may be available for this condition.
There are several orphan drugs designated for the treatment of intermediate cell type uveal melanoma, including tebentafusp-tebn and others currently in development. These drugs may provide new avenues for treatment, although specific clinical trial data is not available at this time. For ongoing research and potential clinical trials, you can search ClinicalTrials.gov for updates on uveal melanoma studies.
Actionable guidance for navigating care for intermediate cell type uveal melanoma
To navigate your care effectively, consider seeking a specialist in ocular oncology or a medical oncologist with experience in melanoma. It may also be beneficial to connect with a genetic counselor to discuss any potential genetic implications, even though no specific genes have been identified. For further resources, the National Organization for Rare Disorders (NORD) offers support and information at rarediseases.org. Additionally, inquire about any natural history studies that may be available for this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding intermediate cell type uveal melanoma is primarily due to its rarity, which restricts the volume of systematic clinical studies. Additionally, the lack of identified genetic markers and phenotypic characterization further complicates the understanding of this condition. As research continues, there is hope for more comprehensive insights.
To navigate your care effectively, consider seeking a specialist in ocular oncology or a medical oncologist with experience in melanoma. It may also be beneficial to connect with a genetic counselor to discuss any potential genetic implications, even though no specific genes have been identified. For further resources, the National Organization for Rare Disorders (NORD) offers support and information at rarediseases.org. Additionally, inquire about any natural history studies that may be available for this condition.
There are several orphan drugs designated for the treatment of intermediate cell type uveal melanoma, including tebentafusp-tebn and others currently in development. These drugs may provide new avenues for treatment, although specific clinical trial data is not available at this time. For ongoing research and potential clinical trials, you can search ClinicalTrials.gov for updates on uveal melanoma studies.
Actionable guidance for navigating care for intermediate cell type uveal melanoma
To navigate your care effectively, consider seeking a specialist in ocular oncology or a medical oncologist with experience in melanoma. It may also be beneficial to connect with a genetic counselor to discuss any potential genetic implications, even though no specific genes have been identified. For further resources, the National Organization for Rare Disorders (NORD) offers support and information at rarediseases.org. Additionally, inquire about any natural history studies that may be available for this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The limited documentation surrounding intermediate cell type uveal melanoma is primarily due to its rarity, which restricts the volume of systematic clinical studies. Additionally, the lack of identified genetic markers and phenotypic characterization further complicates the understanding of this condition. As research continues, there is hope for more comprehensive insights.
To navigate your care effectively, consider seeking a specialist in ocular oncology or a medical oncologist with experience in melanoma. It may also be beneficial to connect with a genetic counselor to discuss any potential genetic implications, even though no specific genes have been identified. For further resources, the National Organization for Rare Disorders (NORD) offers support and information at rarediseases.org. Additionally, inquire about any natural history studies that may be available for this condition.
There are several orphan drugs designated for the treatment of intermediate cell type uveal melanoma, including tebentafusp-tebn and others currently in development. These drugs may provide new avenues for treatment, although specific clinical trial data is not available at this time. For ongoing research and potential clinical trials, you can search ClinicalTrials.gov for updates on uveal melanoma studies.
Actionable guidance for navigating care for intermediate cell type uveal melanoma
To navigate your care effectively, consider seeking a specialist in ocular oncology or a medical oncologist with experience in melanoma. It may also be beneficial to connect with a genetic counselor to discuss any potential genetic implications, even though no specific genes have been identified. For further resources, the National Organization for Rare Disorders (NORD) offers support and information at rarediseases.org. Additionally, inquire about any natural history studies that may be available for this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.